Asset profile
AZD8630
Unknown / undisclosed
Evidence outlook · results not reported
Levante (NCT06529419) · Asthma
The lead study's design has limits that temper confidence (see the rationale below), and its results have not been reported. This tier describes the design, not an outcome.
Levante (NCT06529419): The study randomized 537 participants across three AZD8630 dose groups and placebo, with participants, care providers, investigators, and outcome assessors quadruple-blinded. Its primary endpoint was a clinical exacerbation-related measure, but the primary comparison cannot yet be judged because results have not been reported.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
66 competitors in this universe: 4 direct rivals (same mechanism and indication), 2 same-class, 60 same-indication; 61 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| AZD8630: this drug | Phase 2 | — | TSLP | ||
| Tezepelumab (Tezspire) | Approved | Monoclonal antibody | TSLP, Thymic stromal lymphopoietin (TSLP), ligand-neutralizing | ||
| Tezepelumab (APFS) | Approved | Monoclonal antibody | TSLP | ||
| GSK5784283 | Phase 3 | Monoclonal antibody | TSLP | ||
| WIN378 | Phase 2 | Monoclonal antibody | TSLP | ||
| CM326 | Phase 3 | Monoclonal antibody | TSLP | ||
| BSI-045B | Phase 2 | Monoclonal antibody | TSLP | ||
| Albuterol (Armstrong Albuterol HFA) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Albuterol / Budesonide (Airsupra) | Approved | Combination | Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor | ||
| Albuterol HFA (Armstrong's) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Albuterol HFA (Proventil HFA) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Albuterol Sulfate (Armstrong) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Albuterol Sulfate (Provenetil-HFA) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Aminophylline | Approved | Small molecule | Phosphodiesterase (multi-subtype) | ||
| Beclomethasone (QVAR) | Approved | Small molecule | Glucocorticoid receptor | ||
| Beclomethasone Dipropionate / Formoterol Fumarate / Glycopyrrolate | Approved | Small molecule | Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination) |
…and 51 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.